Disruption of the NTCP–EGFR receptor complex as a strategy for selective inhibition of hepatitis B and D virus entry
Proceedings of the National Academy of Sciences · 17.11.2026 · 123 (46)
DOI: 10.1073/pnas.2603986123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 10.11.2026. Verfasst von Atsuto Kusunoki und 15 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan. Hauptthemen laut MEDLINE: Organic Anion Transporters, Sodium-Dependent, Hepatitis B virus, Symporters, ErbB Receptors. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED), MEXT | Japan Society for the Promotion of Science (JSPS), MEXT | JST | JST-Mirai Program (Mirai).
Abstract (Originalsprache)
Hepatitis B and D virus (HBV, HDV) enter hepatocytes through a coordinated process mediated by a receptor complex consisting of sodium taurocholate cotransporting polypeptide (NTCP), and host entry cofactors, including epidermal growth factor receptor (EGFR). Here, we established an in vitro assay to evaluate the NTCP–EGFR interaction and identified Oxy229, an oxysterol-based compound that disrupted this molecular interaction. Oxy229 selectively inhibited HBV and HDV infection to HepG2-NTCP cells and primary human hepatocytes. Mechanistic analysis revealed that Oxy229 impaired the relocalization of HBV–NTCP complex from the plasma membrane to intracellular vesicles. Notably, Oxy229 did not compromise the physiological functions of NTCP and EGFR, i.e., bile acid transporter and activation of downstream EGFR signaling pathways including Ras–MAPK and PI3K–Akt pathways, indicating selective inhibition of viral entry. Compound derivative analysis identified Oxy283, which acquired dual inhibitory activity against both NTCP–EGFR interaction and NTCP multimerization, resulting in enhanced anti-HBV potency. These findings establish the functional significance of NTCP–receptor complex formation in the HBV/HDV entry and highlight this machinery as a potential target for antiviral intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan.
- Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan.
- Max BioPharma, Inc., Santa Monica, CA 90404.
- National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan.
- Cell Free Sciences Co., Ltd., Matsuyama 790-8577, Japan.
- Choju Medical Institute, Toyohashi 441-8124, Japan.
ORCID-Profile: Makoto Nagano, Ryo Morishita, Tetsuya Toyoda, Norimichi Nomura, Kazuhiko Katayama, Koichi Watashi
Förderung
- Japan Agency for Medical Research and Development (AMED)
- MEXT | Japan Society for the Promotion of Science (JSPS)
- MEXT | JST | JST-Mirai Program (Mirai)
- Takeda Science Foundation (TSF)
- The Chemo-Sero-Therapeutic Research Institute
- Daiichi Sankyo Foundation of Life Science
Zitieren
APA
Kusunoki, A., Shionoya, K., Stappenbeck, F., Morita, T., Ohashi, H., Kagaya, N., Nagano, M., Mifune, J., Morishita, R., Wang, F., Toyoda, T., Nomura, N., Shin-Ya, K., Katayama, K., Parhami, F., & Watashi, K. (2026). Disruption of the NTCP–EGFR receptor complex as a strategy for selective inhibition of hepatitis B and D virus entry. Proceedings of the National Academy of Sciences, 123(46). https://doi.org/10.1073/pnas.2603986123
Vancouver
Kusunoki A, Shionoya K, Stappenbeck F, Morita T, Ohashi H, Kagaya N, et al. Disruption of the NTCP–EGFR receptor complex as a strategy for selective inhibition of hepatitis B and D virus entry. Proceedings of the National Academy of Sciences. 2026;123(46). doi:10.1073/pnas.2603986123
BibTeX
@article{Kusunoki2026,
author = {Kusunoki, Atsuto and Shionoya, Kaho and Stappenbeck, Frank and Morita, Takeshi and Ohashi, Hirofumi and Kagaya, Noritaka and Nagano, Makoto and Mifune, Junki and Morishita, Ryo and Wang, Feng and Toyoda, Tetsuya and Nomura, Norimichi and Shin-Ya, Kazuo and Katayama, Kazuhiko and Parhami, Farhad and Watashi, Koichi},
title = {Disruption of the NTCP–EGFR receptor complex as a strategy for selective inhibition of hepatitis B and D virus entry},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {46},
doi = {10.1073/pnas.2603986123}
}
EUVIMED